DocumentRX-3355
Issued
Read3 min

FDA Opens Its Approval Files to World Regulators With GRDP

FDA's Global Reliance Disclosure Program, launched October 30, 2026, lets drugmakers share redacted approval assessments with foreign regulators, starting with PEPFAR tentative approvals and lenacapavir.

TAG E-4696 · 534 words on the filing

US FDA Launches Global Reliance Disclosure Program for Medicines - Voice of Healthcare
US FDA Launches Global Reliance Disclosure Program for Medicines - Voice of HealthcarePublicDomainPictures / pixabay

Summary of findings

  • FDA launched the Global Reliance Disclosure Program on October 30, 2026, opening minimally redacted approval packages to foreign regulators.
  • Initial scope covers PEPFAR tentative approvals, starting with lenacapavir for HIV prevention and treatment.
  • Eligibility expands in January 2027 to all NME applications and certain BLAs, with a second pathway for already-approved medicines in early 2027.
  • Applicants must request participation within 10 calendar days of approval and confirm foreign marketing-application use.

The FDA launched the Global Reliance Disclosure Program on October 30, 2026, letting drugmakers hand its scientific approval assessments to regulators outside the United States. The goal is simple: cut duplicated reviews and compress national approval timelines, while each country keeps the final say on its own decisions.

Under the program, pharmaceutical companies can request minimally redacted FDA approval packages — detailed scientific evaluations and regulatory assessments included — and share them with foreign regulatory authorities. The FDA frames this as access policy, not a shift in sovereignty. Countries retain authority over their regulatory decisions; they just get to work from the agency's homework rather than repeat it.

What did FDA officials say about it?

Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs, tied the initiative directly to the administration's politics. "The GRDP is a prime example of America First policies improving public health worldwide," she said. She added: "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America's continued interest in advancing global health under the Trump Administration."

Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy, took a more multilateral tone. "In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA's leadership is most effective when it is collaborative," Abdoo said. "The GRDP reflects a forward-looking vision of regulatory leadership: one defined not by exclusivity, but by the willingness to share expertise, elevate global standards, and put patients first — wherever they are."

What does the program cover today — and what comes next?

The scope is staged, and sponsors should note the dates:

  • Launch, October 30, 2026: The program initially covers President's Emergency Plan for AIDS Relief (PEPFAR) tentative approvals. Lenacapavir, indicated for HIV prevention and treatment, is the first medicine in the scheme.
  • January 2027: Eligibility expands to all novel drugs and biologics, spanning New Molecular Entity applications and certain Biologics License Applications.
  • Early 2027: The FDA plans a second pathway for applicants seeking approval packages for medicines already approved in the United States.

What do applicants have to do?

The mechanics carry a tight clock. Eligible applicants must request participation within 10 calendar days of approval. They must also confirm the documentation will support a marketing application submitted to a foreign regulatory authority — this is a disclosure program for reliance routes, not a general records dump.

Why does it matter?

The initiative targets a familiar bottleneck: regulatory delay, particularly in countries with limited regulatory resources that struggle to run full standalone reviews of complex applications. By making the FDA's detailed assessments transferable, the agency expects national regulators to accelerate their own approval processes, strengthen international cooperation and improve access to quality medicines.

For pipeline owners, the practical upside is faster sequential approvals in reliance jurisdictions — and, starting in early 2027, a route to leverage packages for products already on the US market. The 10-day request window is the operational detail most likely to catch sponsors off guard; filing teams will need to flag eligible approvals at decision time, not at international-filing planning months later.

via FDA industry wire (Google News) (Source)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

6 articles

Linked filings

  1. P-6323
  2. E-9124
  3. T-7549
  4. P-1559
  5. K-6477

Next filing »